EUVIMEDEUVIMED entdecken
Crossref

Safety Profile of Lipid Emulsion in Clinical Practice: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System

Akira Okada, Shoji Sera, Koki Takeda, Naomi Nagai

Annals of Nutrition and Metabolism · 2024

DOI: 10.1159/000540111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nutrition and Metabolism, 2024. Verfasst von Akira Okada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Nishi-Tokyo, Japan. Hauptthemen laut MEDLINE: Pharmacovigilance, Fat Emulsions, Intravenous, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lipid emulsion preparations, known for their clinical utility, are associated with various adverse events related to lipid metabolism. In this study, we analyzed the safety profile of lipid emulsions in clinical practice, using a real-world database.

Methods

The US Food and Drug Administration Adverse Event Reporting System database was used to retrieve adverse events associated with lipid emulsion use. The risk of adverse events was evaluated based on the reported odds ratio and time-to-onset analysis.

Results

A total of 4,430 relevant adverse event reports were identified. Hepatic dysfunction tended to occur in the early stages after administration, regardless of the lipid emulsion type. The incidence of hepatic dysfunction varies depending on the triglyceride content of the administered lipid emulsion. Infection tended to occur in the early stages of lipid emulsion administration; however, the incidence did not significantly differ depending on triglyceride content.

Conclusion

Our study revealed adverse lipid emulsion events, indicating the need for comprehensive safety management, particularly in the early stages, for clinical use. Particularly, patients receiving parenteral nutrition, irrespective of lipid emulsion administration, necessitate thorough monitoring of liver function and triglyceride levels and reassessment of infusion rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceFat Emulsions, IntravenousAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationTriglyceridesHumansUnited StatesFemaleMaleParenteral NutritionMiddle AgedDatabases, FactualAdultAgedIncidence

Stichwörter der Autor:innen

Adverse eventsFAERS databaseLipid emulsionReal-world data

Substanzen

Fat Emulsions, IntravenousTriglycerides

Autor:innen und Institutionen

  • Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Nishi-Tokyo, Japan.
  • Research Institute of Pharmaceutical Sciences, Musashino University, Nishi-Tokyo, Japan.

Zitieren

APA

Okada, A., Sera, S., Takeda, K., & Nagai, N. (2024). Safety Profile of Lipid Emulsion in Clinical Practice: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System. Annals of Nutrition and Metabolism. https://doi.org/10.1159/000540111

Vancouver

Okada A, Sera S, Takeda K, Nagai N. Safety Profile of Lipid Emulsion in Clinical Practice: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System. Annals of Nutrition and Metabolism. 2024. doi:10.1159/000540111

BibTeX
@article{Okada2024,
  author = {Okada, Akira and Sera, Shoji and Takeda, Koki and Nagai, Naomi},
  title = {Safety Profile of Lipid Emulsion in Clinical Practice: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System},
  journal = {Annals of Nutrition and Metabolism},
  year = {2024},
  doi = {10.1159/000540111}
}
Kostenlos starten →